Interpace Biosciences Inc
Moat Score — Interpace Biosciences Inc
Total Moat Score
8 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | ThyGeNEXT's mutation/fusion panel and the ThyraMIRv2 11-microRNA classifier are proprietary, clinically validated tests that took years of assay development to build, but they trail Veracyte's Afirma in breadth of validation data and market recognition. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a small-scale lab processing far fewer samples than Veracyte or Sonic Healthcare, Interpace lacks the per-test cost advantages that come with larger testing volumes and deeper payer contracting infrastructure. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | Interpace is out-of-network with most commercial payers and saw CMS unilaterally end Medicare coverage for its PancraGEN test in 2025, showing the company has little control over what it is actually paid per test. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Thyroid molecular diagnostics is a direct physician-to-lab testing relationship with no meaningful network effect; more patients tested does not make the ThyGeNEXT/ThyraMIRv2 product inherently more valuable to the next physician. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Ordering physicians build familiarity and trust with a specific test's reporting format and turnaround time, creating mild habit-based stickiness, but there is no technical or contractual barrier stopping an endocrinologist from switching to Afirma or ThyroSeq. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The roughly $300 million U.S. thyroid assay market is a real niche but not one with natural capacity limits, and it already supports several well-funded competitors (Veracyte, Quest, Sonic Healthcare), leaving room for further entry. |